Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of QUC398 in symptomatic knee osteoarthritis
2021-002795-39Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in knee osteoarthritis (OA) comparing QUC398 with Placebo (2 arms). Primary endpoint: KOOS Pain change at Week 12. Started Aug 2022; status: active.
02
Drugs
QUC398
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2021-002795-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002795-39.